Viridian Therapeutics, Inc. VRDN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $176.35M-17.0% | $212.38M+25.2% | $169.65M+44.6% | $117.32M+1.0% | $116.22M+16.7% | ||
| $585.84M-11.5% | $662.27M+106% | $321.25M-28.0% | $446.03M-14.3% | $520.42M-15.8% | ||
| $784.74M-12.2% | $894.23M+56.4% | $571.91M-1.2% | $578.75M-11.9% | $657.24M-11.0% | ||
| $1.13M-8.0% | $1.23M+9.2% | $1.13M+3.1% | $1.09M-6.1% | $1.16M-6.0% | ||
| $789.02M-12.3% | $899.42M+55.8% | $577.14M-0.9% | $582.32M-11.9% | $660.98M-11.0% | ||
| $13.31M+53.3% | $8.68M-13.7% | $10.06M+18.1% | $8.52M+119% | $3.89M+81.3% | ||
| $274K-25.3% | $367K-1.3% | $372K+29.2% | $288K0.0% | $288K0.0% | ||
| $51.81M-26.7% | $70.7M+39.5% | $50.7M-3.6% | $52.59M+55.9% | $33.73M-29.6% | ||
| $36.09M+5.4% | $34.24M+63.9% | $20.89M+69.1% | $12.35M-40.3% | $20.69M— | ||
| $12.5M-37.6% | $20.03M-73.0% | $74.17M+10.4% | $67.16M+18.8% | $56.51M-20.1% | ||
| 200M0.0% | 200M0.0% | 200M0.0% | 200M0.0% | 200M+24,591% | ||
| -$1.44B-7.8% | -$1.34B-9.9% | -$1.22B-2.9% | -$1.18B-9.3% | -$1.08B-8.7% | ||
| $636.01M-11.9% | $722.17M+43.6% | $502.97M-2.4% | $515.17M-14.8% | $604.47M-10.0% | ||
| $789.02M-12.3% | $899.42M+55.8% | $577.14M-0.9% | $582.32M-11.9% | $660.98M-11.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viridian Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 15.15 — current assets exceed current liabilities.
- Where does Viridian Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.